Schrickel, Jan Wilko
Beiert, Thomas
Linhart, Markus
Luetkens, Julian A.
Schmitz, Jennifer
Schmid, Matthias
Hindricks, Gerhard
Arentz, Thomas
Stellbrink, Christoph
Deneke, Thomas
Bogossian, Harilaos
Sause, Armin
Steven, Daniel
Gonska, Bernd-Dieter
Rudic, Boris
Lewalter, Thorsten
Zabel, Markus
Geisler, Tobias
Schumacher, Burghard
Jung, Werner
Kleemann, Thomas
Luik, Armin
Veltmann, Christian
Coenen, Martin
Nickenig, Georg
Funding for this research was provided by:
Boehringer Ingelheim (ODIn-AF)
Universitätsklinikum Bonn
Article History
Received: 8 August 2023
Accepted: 29 September 2023
First Online: 3 November 2023
Declarations
:
: GN: honoraria for lectures or advisory boards, participation in clinical trials, research funding: Bayer, Boehringer Ingelheim, Daiichi Sankyo, BMS/Pfizer; JWS: honoraria for lectures, research funding: Boehringer Ingelheim, Bayer, Daiichi Sankyo, BMS/Pfizer; TL: moderate honoraria for lectures, research funding or advisory boards: Abbott, Atricure, Boston Scientific, Biotronik, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Pfizer; TG: speaker, consultant fees or research grants from Astra Zeneca, Bayer, BMS/Pfizer, Boehringer Ingelheim, Daiichi Sankyo, Edwards Lifescience, Ferrer/Chiesi, Medtronic not related to the submitted work; TB, ML, JAL, JS, MS, GH, TA, CS, TD, HB, AS, DS, BDG, BR, MZ, BS, WJ, TK, AL, CV, MC: no disclosures related to submitted work.